Lexinfintech Holdings Ltd
Financial Services
Lexinfintech Holdings Ltd (LX) Stock News
The latest LX headlines and market coverage — 10 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Calix, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CALX
Rosen Law Firm has filed a class action lawsuit against Calix, Inc. on behalf of investors who purchased securities between January 28, 2026 and April 21, 2026. The lawsuit alleges that Calix made false and misleading statements regarding its profit margins, claiming the company benefited from advanced memory component purchases in Q1 but failed to disclose that supplies were dwindling and the company faced negative margin pressure from rising component costs. Investors who wish to serve as lead plaintiff must file by July 27, 2026.
- The Motley Fool·
BingEx (FLX) Q4 2025 Earnings Transcript
BingEx reported flat Q4 2025 revenue of RMB 1 billion but achieved strong profitability improvements with non-GAAP net income surging 107% year-over-year to RMB 41.6 million. The company improved gross margins to 10.8% through operational refinement and strategic focus on high-value delivery segments like electronics (up 17% YoY) and cake delivery (up 5% YoY). BingEx expanded its network to 298 cities with 31 million riders and launched drone delivery pilots in Hangzhou with over 2,000 orders completed, while deploying AI across operations to boost development efficiency by 30%.
- GlobeNewswire Inc.·
CALX Shareholder Alert: Calix, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
Calix, Inc. faces a securities class action lawsuit for allegedly concealing that record gross margins between January-April 2026 were temporarily sustained by pre-purchased lower-cost memory components. The company failed to disclose margin pressures until April 21, 2026, when it revealed declining margins due to exhausted inventory and rising memory costs, triggering a 13.98% stock decline. Investors who purchased shares during the class period may be eligible for damages.
- GlobeNewswire Inc.·
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
Monopar Therapeutics announced Phase 2 trial results for ALXN1840 (tiomolibdate choline) in treatment-experienced Wilson disease patients. The study demonstrated stabilization or improvement in liver pathology across multiple histologic measures, significant neurologic improvements in UWDRS scores, and improved quality of life. The drug was generally well tolerated with mostly Grade 1-2 adverse events.
- GlobeNewswire Inc.·
ROSEN, LEADING INVESTOR COUNSEL, Encourages Calix, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CALX
Rosen Law Firm has filed a class action lawsuit against Calix, Inc. on behalf of investors who purchased securities between January 28, 2026 and April 21, 2026. The lawsuit alleges that Calix made false and misleading statements regarding its margins, claiming the company benefited from advanced memory component purchasing in Q1 but failed to disclose that supplies were dwindling and the company faced negative margin pressure from rising component costs. Investors who wish to serve as lead plaintiff must file by July 27, 2026.
- GlobeNewswire Inc.·
CALIX, INC. (CALX) INVESTOR ALERT Investors With Large Losses in Calix, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Bernstein Liebhard LLP has announced shareholder class action lawsuits against three companies: Calix (CALX) for alleged misrepresentations regarding business operations and financial stability during January-April 2026; AeroVironment (AVAV) for shareholders between June 2025 and March 2026; and Zoetis (ZTS) for shareholders between January 2025 and May 2026. Investors are encouraged to contact the firm to discuss their rights and potential recovery.
- GlobeNewswire Inc.·
ROSEN, LEADING INVESTOR COUNSEL, Encourages Calix, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CALX
Rosen Law Firm has filed a class action lawsuit on behalf of Calix, Inc. investors who purchased securities between January 28, 2026 and April 21, 2026. The lawsuit alleges that Calix made false and misleading statements regarding profit margins, claiming the company benefited from advanced memory component purchasing in Q1 but failed to disclose that supplies were dwindling and the company faced negative margin pressure from rising component costs. Investors who suffered losses are encouraged to join the class action by July 27, 2026.
- Benzinga·
RLX Technology Announces Unaudited First Quarter 2026 Financial Results
SHENZHEN, China , May 20, 2026 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE: RLX ), a leading global branded e-vapor company, today announced its unaudited financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Net revenues were RMB1,585.8 million (US$229.9 million) in the first quarter of 2026, increasing by 96.2% from RMB808.3 million in the same period of 2025. Gross margin was 31.8% in the first quarter of 2026, compared with 28.6% in the same period of 2025. Non-GAAP income from operations [1] was RMB310.3 million (US$45.0 million) in the first quarter of 2026, increasing by 187.9% from RMB107.8 million in the same period of 2025. U.S. GAAP net income was RMB294.2 million (US$42.6 million) in the first quarter of 2026, increasing by 32.1% from RMB222.7 million in the same period of 2025. Non-GAAP net income [1] was RMB357.3 million (US$51.8 million) in the first quarter of 2026, increasing by 41.4% from RMB252.7 million in the same period of 2025. "We began this year with robust first-quarter results, underpinned by a highly scalable global ecosystem and our ability to capture emerging market opportunities," said Ms. Ying (Kate) Wang, Co-founder, Chairperson, and Chief Executive Officer of RLX Technology. "We continued to accelerate our international expansion and broaden our global operations. Notably, we refined our user-first approach through highly localized strategies and deep engagement with trusted regional business partners to ensure superior product-market fit, strengthening our global competitiveness. We also integrated our R&D, manufacturing, and commercial operations into Nexus, our cutting-edge hub that is driving greater supply chain efficiencies while allowing us to seamlessly meet rising demand. Looking ahead, we will build on this momentum by focusing on innovativ
- GlobeNewswire Inc.·
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
Telix Pharmaceuticals announced completion of patient enrolment in the IPAX-2 Phase 1 study of TLX101-Tx (¹³¹I-iodofalan) for newly diagnosed glioblastoma. The study reached its maximum dose of 10GBq with no dose-limiting toxicities observed. The company is also advancing the pivotal IPAX BrIGHT Phase 3 trial for recurrent glioblastoma, marking the first radiopharmaceutical therapy to enter Phase 3 development for this indication.
- GlobeNewswire Inc.·
CALX SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Law firm Kirby McInerney LLP is investigating Calix, Inc. for potential securities law violations following the company's April 21, 2026 earnings report. Calix reported declining gross margins and warned of further margin compression due to exhausted advanced supply purchases, causing the stock to drop 14% ($6.93 per share) on April 22, 2026. The firm is seeking investors who purchased Calix securities to discuss potential claims.